Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Background The development of anti-HER2 antibody–drug conjugates opens new
therapeutic options for patients with breast cancer, including patients with low expression of …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …